Korro Bio, Inc. (KRRO)

Korro Bio's stock experienced significant volatility. In November 2025, the stock declined sharply due to the failure of KRRO-110, accompanied by workforce reductions and a pause in the Novo Nordisk partnership. In March 2026, a PIPE financing and at-the-market share sales increased cash reserves, extending the cash runway into the second half of 2028. In May 2026, several analyst firms upgraded the stock rating based on positive preclinical data and first-quarter results, leading to a rebound in the stock price year-to-date.

Korro Bio, as a clinical-stage biopharmaceutical company, does not exhibit typical demand seasonality. Demand for its pipeline candidates will be driven by the prevalence of targeted diseases and the clinical efficacy and safety of its therapies. Revenue generation is currently tied to collaboration agreements and the successful advancement of drug candidates.

Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on RNA editing to treat rare and prevalent diseases. Their OPERA™ platform aims to offer precise and tunable genetic medicines. KRRO-110, their initial candidate for AATD, failed in Phase 1/2a trials. The company is now advancing KRRO-121 for urea cycle disorders, with a regulatory submission expected in the second half of 2026. They are also developing a new GalNAc-conjugated RNA editor for AATD, aiming for clinical trials in 2027. A partnership with Novo Nordisk focused on cardiometabolic diseases was paused for 12 months in November 2025.

Korro Bio, Inc. is headquartered in Cambridge, Massachusetts, United States.

Korro Bio's brand reputation was negatively impacted in November 2025 due to the clinical trial failure of KRRO-110, workforce reductions, and the pausing of the Novo Nordisk partnership. However, renewed investor confidence was demonstrated by a successful private placement and at-the-market share sales in March 2026. Analyst upgrades in May 2026, driven by promising preclinical data and a strategic pivot, indicate a more positive outlook. Continued focus on the OPERA™ platform and advancement of new candidates are crucial for rebuilding its brand reputation.

Korro Bio has a diverse ownership structure, with 43.8% held by institutional shareholders, 4.02% by individual insiders, 5.66% by hedge funds, 23.9% by VC/PE firms, and 22.7% by the general public. Major institutional owners include Atlas Venture Life Science Advisors, LLC, NEA Management Company, LLC, and Vanguard Group Inc. Notable individual insiders include Rick Yang, Anthony A. Florence Jr., and Mohamad Makhzoumi, each owning 16.44% of the company. Mohamad Makhzoumi made a significant insider purchase in March 2026.